Anti-SMAD3 Antibody


Reactivity: Human
Applications: ELISA,WB,IHC,IP
Conjugation: Various

-$50 as credit for submitting review for primary antibody
Shipping notice:
Product will be delivered in 6 to 8 Business Days

Rabbit Anti-SMAD3 Antibody (CSB-PA021788ESR2HU)


Alternative names:

MAD homolog 3 Antibody,Mad3 Antibody,Mothers against DPP homolog 3 Antibody,hMAD-3 Antibody,JV15-2 Antibody,SMAD family member 3 Antibody, SMAD 3 Antibody,Smad3 Antibody, hSMAD3 Antibody,SMAD3 Antibody,MADH3 Antibody

More alternative names for the antibody
hMAD 2 antibody|SMAD 2 antibody|SMAD 3 antibody|SMAD family member 2 antibody|SMAD family member 3 antibody|smad2+3 antibody|smad2/3 antibody
Anti-Smad2 + Smad3 antibody [EPR19557-4] – ChIP Grade (ab202445)
Close sc-11769|sc-130218|sc-514317|sc-165305|sc-515132|sc-74864|sc-390878|sc-100454|sc-100455|sc-71790|sc-56746|

Recommended applications: ELISA, WB, IHC, IP

Recommended dilution: Recommended dilution:WB:1:1000-1:5000,IHC:1:20-1:200,IP:1:200-1:2000

Recommended protocols: check protocols


Anti-SMAD3 Antibody

Catalogue No.





Recombinant human Mothers against decapentaplegic homolog 3 protein (1-230AA)





Recommended dilution

Recommended dilution:WB:1:1000-1:5000,IHC:1:20-1:200,IP:1:200-1:2000







Molecular weight

48 kDa


Antigen Affinity Purified


Shipped at 4 Celcius Degree. Upon delivery aliquot and store at -20 Celcius Degree or -80 Celcius Degree. Avoid repeated freeze.

Database links

Entrez Gene:4087( Human), Entrez Gene:4088( Human), Entrez Gene:17126( Mouse), Entrez Gene:17127( Mouse), Entrez Gene:25631( Rat), Entrez Gene:29357( Rat), Omim:601366( Human), Omim:603109( Human), SwissProt:P84022( Human), SwissProt:Q15796( Human), SwissProt:Q62432( Mouse), SwissProt:Q8BUN5( Mouse), SwissProt:O70436( Rat), SwissProt:P84025( Rat)

Protein function

Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF-mediated chemotaxis of monocytes. This effect on wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. .

Involvement in disease

Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. . Note=The disease may be caused by mutations affecting the gene represented in this entry.; Loeys-Dietz syndrome 3 (LDS3) [MIM:613795]: An aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. Patients with LDS3 also manifest early-onset osteoarthritis. They lack craniosynostosis and mental retardation. . Note=The disease is caused by mutations affecting the gene represented in this entry. SMAD3 mutations have been reported to be also associated with thoracic aortic aneurysms and dissection (TAAD) (PubMed:21778426). This phenotype is distinguised from LDS3 by having aneurysms restricted to thoracic aorta. As individuals carrying these mutations also exhibit aneurysms of other arteries, including abdominal aorta, iliac, and/or intracranial arteries (PubMed:21778426), they have been classified as LDS3 by the OMIM resource. .

Protein sequence and domain

Belongs to the dwarfin/SMAD family. The MH1 domain is required for DNA binding. Also binds zinc ions which are necessary for the DNA binding.; The MH2 domain is required for both homomeric and heteromeric interactions and for transcriptional regulation. Sufficient for nuclear import.; The linker region is required for the TGFbeta-mediated transcriptional activity and acts synergistically with the MH2 domain.

Protein post-translational modifications

Phosphorylated on serine and threonine residues. Enhanced phosphorylation in the linker region on Thr-179, Ser-204 and Ser-208 on EGF and TGF-beta treatment. Ser-208 is the main site of MAPK-mediated phosphorylation. CDK-mediated phosphorylation occurs in a cell-cycle dependent manner and inhibits both the transcriptional activity and antiproliferative functions of SMAD3. This phosphorylation is inhibited by flavopiridol. Maximum phosphorylation at the G(1)/S junction. Also phosphorylated on serine residues in the C-terminal SXS motif by TGFBR1 and ACVR1. TGFBR1-mediated phosphorylation at these C-terminal sites is required for interaction with SMAD4, nuclear location and transactivational activity, and appears to be a prerequisite for the TGF-beta mediated phosphorylation in the linker region. Dephosphorylated in the C-terminal SXS motif by PPM1A. This dephosphorylation disrupts the interaction with SMAD4, promotes nuclear export and terminates TGF-beta-mediated signaling. Phosphorylation at Ser-418 by CSNK1G2/CK1 promotes ligand-dependent ubiquitination and subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF-beta responses. Phosphorylated by PDPK1. .; Acetylation in the nucleus by EP300 in the MH2 domain regulates positively its transcriptional activity and is enhanced by TGF-beta. .; Poly-ADP-ribosylated by PARP1 and PARP2. ADP-ribosylation negatively regulates SMAD3 transcriptional responses during the course of TGF-beta signaling. .; Ubiquitinated. Monoubiquitinated, leading to prevent DNA-binding (PubMed:21947082). Deubiquitination by USP15 alleviates inhibition and promotes activation of TGF-beta target genes (PubMed:21947082). Ubiquitinated by RNF111, leading to its degradation: only SMAD3 proteins that are ‘in use’ are targeted by RNF111, RNF111 playing a key role in activating SMAD3 and regulating its turnover (By similarity). Undergoes STUB1-mediated ubiquitination and degradation (PubMed:24613385). .

Protein cellular localization

Cytoplasm . Nucleus . Note=Cytoplasmic and nuclear in the absence of TGF-beta. On TGF-beta stimulation, migrates to the nucleus when complexed with SMAD4 (PubMed:15799969). Through the action of the phosphatase PPM1A, released from the SMAD2/SMAD4 complex, and exported out of the nucleus by interaction with RANBP1 (PubMed:16751101, PubMed:19289081). Co-localizes with LEMD3 at the nucleus inner membrane (PubMed:15601644). MAPK-mediated phosphorylation appears to have no effect on nuclear import (PubMed:19218245). PDPK1 prevents its nuclear translocation in response to TGF-beta (PubMed:17327236). .

Research area

All research areas>Transcription Regulators>Smad
(View all antibody categories related to Transcription Regulators)


AntibodyPlus provides antibody trial sample for your own antibody validation and collects antibody reviews.



Product type

Primary antibody


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review

There are no reviews for this product yet.
By submitting a review, get following benefits:

1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!

view database submit reviews

There is no extra validation for this product yet.
Check other extra validated antibodies below:

Welcome to AntibodyPlus!